Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.140
-0.270 (-6.12%)
At close: Jan 15, 2026, 4:00 PM EST
4.290
+0.150 (3.62%)
Pre-market: Jan 16, 2026, 9:28 AM EST
Precigen Employees
Precigen had 143 employees as of December 31, 2024. The number of employees decreased by 59 or -29.21% compared to the previous year.
Employees
143
Change (1Y)
-59
Growth (1Y)
-29.21%
Revenue / Employee
$44,119
Profits / Employee
-$2,978,084
Market Cap
1.46B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 143 | -59 | -29.21% |
| Dec 31, 2023 | 202 | -7 | -3.35% |
| Dec 31, 2022 | 209 | -302 | -59.10% |
| Dec 31, 2021 | 511 | 34 | 7.13% |
| Dec 31, 2020 | 477 | -380 | -44.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PGEN News
- 20 hours ago - Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 10 days ago - Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Precigen Is Still A Buy After The Papzimeos Rally - Seeking Alpha
- 2 months ago - Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PRNewsWire
- 2 months ago - Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 - PRNewsWire
- 3 months ago - Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire